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Introduction 
 
Superficial bladder cancer constitutes 75-80% of all bladder 
carcinomas. Various combinations from low stage low grade to high stage 
and grade tumors occur with widely varying potential to invade and 
metastasize. 
  
Initial transvesical resection can give us the correct stage and grade 
based on which further adjuvant therapy is planed. Adjuvant intravesical 
chemotherapy or immunotherapy has shown significant cancer free survival 
when compared to TUR alone. 
 
 Morales and associates first reported the use of BCG in the treatment 
of superficial bladder cancer in1976 and since then several papers have 
reaffirmed the effectiveness of BCG in superficial bladder cancer. 
 
BCG which has proven to be an important agent against Superficial 
TCC is not with out its own drawbacks. It has wide ranging side effects 
which limit its use as well as decrease patient compliance. The toxicity is 
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directly linked to the amount of BCG that is instilled into the bladder. Hence 
effort has been directed at reducing the toxicity profile of BCG either by 
reducing the dose of BCG and or by combining BCG with other 
immunomodulators. 
 
 Interferon which is at the forefront of this combination protocol has 
been found to be relatively effective when used alone or in combination with 
BCG in vitro and in vivo. But the dosage, the dose of the combination and 
the treatment schedule has not met with universal consensus. Many 
combinations from low dose of BCG with high doses of interferon and vice 
versa have been tried with varying results. 
 
Hence this study has been envisaged with an idea of combining both 
low dose BCG and low dose interferon and test their efficacy, safety and 
toxicity profile in the management of superficial bladder cancer. 
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Aim 
 
 The aim of the present work is to do a prospective randomized 
comparison of 120mgs of BCG against a combination of 60mgs of BCG and 
6 million international units of interferon alfa 2b as intravesical therapy in 
the treatment of superficial bladder cancer. 
 
So the primary end point would be to see whether this combination of 
low dose interferon and BCG is as efficacious as full dose of BCG. 
 
The secondary endpoints would be to assess the toxicity profile and to 
see whether this compares favorably with full dose of BCG and to see 
whether this combination has a synergistic effect, thereby producing any 
survival benefit or any prevention of progression. 
 
Other parameters like size of the index tumor, multifocality, stage 
grade, incomplete resection, time to recurrence is also being assessed to see 
how these parameters impact survival and natural history of the disease 
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MATERIALS and METHODS 
 
Study design was a prospective randomized trial. 61 patients were 
totally recruited  and randomized into the study over a time frame of 
 8 months and were subjected to the following regimen. After initial TURBT 
(May 03 To Dec 03) and stage and grade assessment and a time gap of   
at least  30 days after TURBT the patients were subjected to intravesical 
BCG 120mgs (Group A ) or BCG 60mg   along with 6 million international 
units of Interferon a2b ( Group B ) with 60ml of physiological saline and 
instilled into the bladder. 
 
This treatment was given every week for 6 weeks and every month for 
6 months accounting for a total of 12 intravesical instillations and further 3 
weekly maintenance dose at the end of 12 months ,18months 24 months 30 
months etc. 
 Each instillation was for a period of two hours in which the patients 
were advised to lie in prone, supine, left and right lateral positions for half 
an hour each.  
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Follow up of the patients included urine cytology for malignant cells, 
USG abdomen and check cystoscopy every 3months for the first year and 
every 6 months for the next 2 years and yearly thereafter and upper tract 
evaluation was done periodically 
 
The strain of BCG that was used was the Danish 1331 strain produced 
in 40mg vials by the BCG vaccine laboratory, Guindy – Chennai. 
Human interferon Alfa 2b, r – DNA (recombinant) was used.  
 
Patient selection 
 
All patients who presented to our unit and were found to have 
superficial bladder cancer  were enrolled into our study. Superficial bladder 
cancer included CIS, T1, and Ta including all grades (except Ta Grade 1 and 
2). All cases excepting CIS were proved by TURBT and for CIS cold cup 
biopsies were used for histopathology. No additional therapy in the form of 
resection or fulguration was used for CIS. A thorough history, clinical 
investigations USG and CT scan with IVP for upper tract evaluation was 
performed. All cases informed written consent was obtained before 
commencement of the procedure. 
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Exclusion criteria 
 
The following exclusion criteria were applied: pregnancy previously 
diagnosed and treated bladder cancer, recurrent bladder cancers, exposure to 
previous therapy with interferon in whatever form, previous therapy for 
pulmonary tuberculosis, muscle invasive bladder cancer and known 
hypersensitivity to either BCG or interferon. Patients with prostatic urethral 
involvement were also excluded from the study. Persons with stricture 
urethra on regular urethral dilatation were also excluded from the study. 
Multiple superficial TCC with majority of lesions in unresectable areas were 
also excluded from the study. 
 
Stages Ta with Grade 1 and 2 were also excluded as these tumors are 
enrolled only   in a surveillance protocol in our unit without any further 
adjuvant therapy. 
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Response criteria 
Response was categorized into complete response, partial response 
and no response or progression. 
 
Complete response was defined as total resolution of the tumor 
confirmed with negative biopsy and cytology. 
 
Partial response was defined as same stage and grade recurrence. 
These cases were usually managed by TUR and then restarting the same 
treatment schedule. 
 
No response or progression was defined as higher stage and grade 
recurrence and development of tumor in new areas in the bladder during the 
treatment schedule. Cases that progressed were taken out of the study and 
invariably went in for radical cystectomy. 
 8
 
Toxicity evaluation 
Toxicity was evaluated by observation by the treating doctors, patient 
reports and local and systemic reactions. A quantitative bladder symptom 
questionnaire and a visual analogue scale which was filled in by patients at 
the time of cystoscopy were used to study the toxicity profile. The severity 
of the adverse reactions was graded according to a subjective and objective 
assessment protocol. Discomfort was graded on a visual analogue scale with 
1 being least toxic and 5 being the worst. Up to a weeks delay was planned 
to be allowed for each instillation if the patient was unable to tolerate the 
drug regimen. 
Statistical analysis 
 Data were entered in excel software and analyzed using SPSS 
software. To examine the statistical significance difference with categorical 
variables, the chi-square test was used.  Kaplan-Meier survival analysis was 
done to examine the distribution of times and duration of disease free status 
after surgery (in months).  Censored cases are cases for which the outcome 
is not known, that are patients are still in follow-up.   
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Review of literature 
Bladder cancer is the second most common urologic 
malignancy after prostate cancer. On histopathology, 93% of bladder 
cancers are transitional cell carcinomas, 5% are squamous cell 
carcinomas, and 2% are adenocarcinomas.  
 
The majority of bladder cancers present as superficial (80%), 
with only 15% presenting as invasive cancer and 5% as metastatic 
disease. Superficial bladder cancers are a heterogeneous group of 
cancers with variable biologic potentials.  
Three “sub stages” are defined  
Ta — papillary tumor confined to the urothelium), 
T1 — papillary tumor invading the underlying lamina propria 
Tcis (carcinoma in situ) — flat, reddened lesions on cystoscopic 
appearance with high-grade histologic 
Features (i.e., changes throughout the whole thickness of the 
urothelium, marked loss of polarity, and easily found mitotic figures) 
but with changes confined to the urothelium 
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only
 
 
 
 
 
 
Ta   Papillary tumor confined to the urothelium 
 
T1  Papillary tumor invading the underlying lamina 
propria   
    
Tcis  Flat, reddened lesion on cystoscopic 
appearance; high-grade histologic features 
confined to the urothelium 
A : Papillary low stage low grade tumor 
B : Sessile grade 3 tumor 
C : Carcinoma insitu  
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Diagnosis and Initial Management 
 
The most common clinical presentation is asymptomatic gross 
or microscopic hematuria. Occasionally, patients present with 
irritative voiding symptoms: 
Dysuria, frequency, and urgency. This symptom complex 
is highly suggestive of carcinoma in situ. The presence of hematuria 
is suggestive of cancer in the urinary tract until proven otherwise. 
Whenever the presence of transitional cell carcinoma is suspected, a 
full urologic evaluation consisting of cystoscopy, urinary cytology, and 
intravenous pyelogram is mandatory. 
  
This evaluation allows for assessment of the whole 
urinary tract since tumor lesions may be located anywhere 
along the upper urinary tract (calyces, renal pelvis, ureters) or lower 
urinary tract (bladder and proximal urethra). When a lesion is noted 
on cystoscopy, the configuration (flat, sessile, or papillary), location 
(trigone, base, right lateral wall, left lateral wall, dome), size (in 
centimeters), and number should be noted. 
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The initial management consists of complete transurethral 
resection of any visible tumors and selected biopsies of the bladder 
mucosa including the prostatic urethra. At the time of resection, an 
examination under anesthesia is performed prior to and following 
resection. The presence of a palpable mass suggests muscle 
invasion by tumor. 
With cystoscopic and pathologic findings, the clinician can determine 
if further treatment with intravesical therapy is required. Additional 
treatment decisions are based on the estimates of risk of recurrence 
and progression. Patients can be stratified in two groups: low risk and 
high risk for recurrence and progression 
 
Low-Risk Group 
In most cases, patients present either with a bladder tumor for the 
first time or with a long interval of time without recurrence. On 
cystoscopy, there may be up to 3 lesions, they could be up to 3 cm in 
size, and they have a papillary configuration. On histopathology, the 
lesions do not invade the lamina propria (stage Ta) and are well or 
moderately differentiated (grade I or II). 
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High-Risk Group 
Patients in this group may present with a bladder tumor for the first 
time, or they may have had multiple recurrences in a short period of 
time. On cystoscopy, there may be more than 3 lesions, they may be 
larger than 3 cm, and they may appear to be less papillary (sessile) in 
configuration. Unfavorable findings include incomplete resection due 
to technical problems (such  as location of the tumor in an area that is 
difficult to resect) or diffuse bladder involvement. Pathologically, 
tumors are high grade and/or invade the lamina propria (T1 lesions). 
The presence of carcinoma in situ alone or associated with papillary 
tumors is also an adverse prognostic sign.   
 
Newer molecular markers are being evaluated to more 
precisely define poor risk. These markers include immunostaining for 
mutated p53, the presence of aneuploidy, and a high proliferation rate 
(Ki-67 immunostain-positive tumors).  
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 Low risk  High risk 
Multiple, frequent 
recurrences 
No Yes 
 
Appearance Papillary, fine 
stalk 
Papillary, thick stalk, or 
sessile 
 
Size 3 cm >3 cm 
 
Number of lesions 3 >3 
Transurethral resection Complete Incomplete 
Stage Ta T1, Tcis 
 
Grade I-II III 
 
 
 
Approximately 70% to 80% of patients with newly diagnosed bladder 
cancer will present with superficial bladder tumors (i.e., stage Ta, Tis, or 
T1). Those who do present with superficial, noninvasive bladder cancer can 
often be cured, and those with deeply invasive disease can sometimes is 
 15
cured by surgery, irradiation, or a combination of modalities that include 
chemotherapy. Studies have demonstrated that some patients with distant 
metastases have achieved long-term complete response following treatment 
with combination chemotherapy regimens.  
 
The major prognostic factors in carcinoma of the bladder are the depth 
of invasion into the bladder wall and the degree of differentiation of the 
tumor.  
 
Most superficial tumors are well differentiated. Patients in whom 
superficial tumors are less differentiated, large, multiple, or associated with 
carcinoma in situ (Tis) in other areas of the bladder mucosa are at greatest 
risk for recurrence and the development of invasive cancer. Such patients 
may be considered to have the entire urothelial surface at risk for the 
development of cancer. Tis may exist for variable durations. Adverse 
prognostic features associated with a greater risk of disease progression 
include the presence of multiple aneuploid cell lines, nuclear p53 over 
expression, and expression of the Lewis-x blood group antigen.1-4 
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  Patients with Tis who have a complete response to bacillus Calmette-
Guérin have approximately a 20% risk of disease progression at 5 years; 
patients with incomplete response have approximately a 95% risk of disease 
progression.1 
 
 Several treatment methods (i.e., transurethral surgery,  
intravesical medications, and cystectomy) have been used in the 
management of patients with superficial tumors, and each method can be 
associated with 5-year survival in 55% to 80% of patient’s treated.1, 2, 5 
 
Invasive tumors that are confined to the bladder muscle on pathologic 
staging after radical cystectomy are associated with approximately a 75% 5-
year progression-free survival rate. Patients with more deeply invasive 
tumors, which are also usually less well differentiated, experience 5-year 
survival rates of 20% to 40% following radical cystectomy. When the 
patient presents with locally extensive tumor that invades pelvic viscera or 
with metastases to lymph nodes or distant sites, 5-year survival is 
uncommon, but considerable symptomatic palliation can still be achieved.6 
 
 17
Expression of the tumor suppressor gene p53 also has been associated 
with an adverse prognosis for patients with invasive bladder cancer. A 
retrospective study of 243 patients treated by radical cystectomy found that 
the presence of nuclear p53 was an independent predictor for recurrence 
among patients with stage T1, T2, or T3 tumors.7 Another retrospective 
study showed p53 expression to be of prognostic value when considered 
with stage or labeling index.8 
 
Stage I bladder cancer is defined by the following TNM classification: 
 
T1, N0, M0 
 
Patients with stage I bladder tumors can be cured by a variety of 
treatments, even though the tendency for new tumor formation is high. In a 
series of patients with Ta or T1 tumors who were followed for a minimum of 
20 years or until death, the risk of bladder recurrence following initial 
resection was 80%.9 Patients at greatest risk of recurrent disease are those 
whose tumors are large, poorly differentiated, multiple, or associated with 
nuclear p53 overexpression10. In addition, patients with carcinoma in situ 
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(Tis) or dysplasia of grossly uninvolved bladder epithelium are at greater 
risk of recurrence and progression.9, 11, 12  
 
Transurethral resection (TUR) and fulguration are the most common 
and conservative forms of management. Careful surveillance of subsequent 
bladder tumor progression is important. One retrospective series addressed 
the value of performing a second TUR within 2 to 6 weeks of the first. 13 
 
A second TUR performed on 58 patients with T1 disease found that 
14 patients (24%) had residual (T1) disease and 16 patients (28%) had 
muscle invasion (T2). Such information may change the definitive 
management options in these individuals. Patients who require more 
aggressive forms of treatment are  
those with extensive multifocal recurrent disease and/or other unfavorable 
prognostic features. Segmental cystectomy is applicable to only a small 
minority of patients because of the tendency of bladder carcinoma to involve 
multiple regions of the bladder mucosa and to occur in areas that cannot be 
segmentally resected.  
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Intravesical therapy with thiotepa, mitomycin, doxorubicin, or bacillus 
Calmette Guérin (BCG) is most often used in patients with multiple tumors 
or recurrent tumors or as a prophylactic measure in high-risk patients after 
TUR.  
 
Administration of intravesical BCG combined with subcutaneous 
BCG following TUR was compared with TUR alone in patients with Ta and 
T1 lesions. Treatment with BCG delayed progression to muscle-invasive 
and/or metastatic disease, improved bladder preservation, and decreased the 
risk of death from bladder cancer.14 Another randomized study in patients 
with superficial bladder cancer also reports a decrease in tumor recurrence in 
patients given intravesical and percutaneous BCG compared with controls.15 
 
 Two nonconsecutive 6-week courses with BCG may be necessary to 
obtain optimal response.16 Patients with a T1 tumor at the 3-month 
evaluation after a 6-week course of BCG and patients with Tis that persists 
after a second 6-week BCG course have a high likelihood of developing 
muscle-invasive disease and should be considered for cystectomy.16 – 18 
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A randomized study that compared intravesical and subcutaneous 
BCG to intravesical doxorubicin showed better response rates and freedom 
from recurrence with the BCG regimen for recurrent papillary tumors as 
well as for Tis.19 Preliminary results of 1 study have shown a possible 
survival benefit with maintenance BCG after a 6-week induction course.20 
 
 Another study that compared alternating mitomycin and BCG with 
BCG alone, both given for 24 months, found that the efficacy was equal, but 
that the side effects of the combined regimen were slightly less.21 A similar 
trial comparing sequential mitomycin and BCG to mitomycin alone also 
found no major differences in toxic effects or efficacy.22 
 
 A randomized trial from the Swedish-Norwegian Bladder Cancer 
Group compared 2 years of intravesical treatment with mitomycin C versus 
BCG for patients at high risk for recurrence or progression. At 5 years, a 
significant improvement was noted in disease-free survival with BCG (P = 
.04); however, no difference was observed in tumor progression or overall 
survival between the 2 arms.23 
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Standard treatment options:  
 
1. TUR with fulguration.24,25  
 
2. TUR with fulguration followed by intravesical BCG.14,15,17,18,21  
 
3. TUR with fulguration followed by intravesical chemotherapy.11,21  
 
4. Segmental cystectomy (rarely indicated).24  
 
5. Radical cystectomy in selected patients with extensive or refractory 
superficial tumor. 26 
 
6. Interstitial implantation of radioisotopes with or without external-
beam irradiation.27,28  
 
Treatment options under clinical evaluation:  
1. Use of chemoprevention agents after treatment to prevent 
recurrence.29 
2. Intravesical therapies. 
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Background Of BCG Therapy 
 
BCG immunotherapy is currently acknowledged by most urologists to 
be the best available intravesical treatment available for superficial and in 
situ transitional cell carcinoma (TCC) of the bladder. With the possible 
exception of interferon treatment for hairy cell leukemia, which can achieve 
90% complete response, BCG treatment appears to be the most effective 
application of immunotherapy to the treatment of human cancer. With 
current optimal induction protocols, 82% of patients with carcinoma in situ 
(CIS) will be expected to have complete response to BCG, and long-term 
follow-up reveals that 64% of those who respond will remain disease-free 
for 5 or more years. 
 
The development of BCG immunotherapy in bladder cancer has been 
the result of both clinical and laboratory research throughout the world.  
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Background 
Holmgren in Sweden was the first to report the use of BCG to treat 
cancer in humans in 1935 30. Some successes occurred in 28 patients, but the 
report was largely ignored. The profound immunostimulatory effect of BCG, 
particularly the stimulation of the reticuloendothelial system, led 
investigators to evaluate the role of BCG in the treatment of tumours in 
experimental animals in the 1950s. Success in animal trials led to numerous 
clinical trials, and early reports of these clinical trials were highly 
encouraging. Unfortunately, subsequent controlled trials in numerous 
tumour types, many of which were carried out in patients with advanced 
disease, failed to confirm the benefit of BCG immunotherapy. However, 
with documented response in patients with melanoma and other cutaneous 
malignancies, and the obvious analogy to bladder cancer, investigators 
began laboratory and clinical investigations in the early 1970s.  
 
At the University of California, Los Angeles, the intralesional 
injection of BCG in a patient with melanoma of the bladder was shown to be 
feasible 31, and subsequent studies in dogs confirmed that delayed-type 
hypersensitivity (DTH) responses could be induced with BCG injection in 
the bladder.32 At the University of California, San Diego, D Lamm et al 
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initiated controlled evaluations of BCG immunotherapy in 1973, using a rat 
bladder tumour model. In this study, repeated BCG treatment significantly 
reduced tumour growth compared with controls .33 
 
Clearly, the most important early contribution to the development of 
BCG immunotherapy came in 1976, when Morales reported his clinical trial 
of BCG in 9 patients with recurrent tumours .34 He observed a 12-fold 
reduction in the rate of tumour recurrence when patients were used as their 
own control. The empirically selected treatment protocol, which involved 6 
weekly treatments consisting of percutaneous BCG plus an instillation of 
120 mg (109 colony-forming units [CFU]) BCG diluted in 50 ml 
physiological saline, retained for 2 hours, was remarkably close to the 
current optimal treatment regimen. This study was the one on which 
subsequent controlled trials in the USA were based.  
 
Confirmation of Efficacy in Controlled Trials 
Based on Morales’ encouraging preliminary data, the US National 
Cancer Institute funded two prospective randomized trials of BCG versus 
standard transurethral resection (TUR) alone. D Lamm et al   trial was first 
reported in 1979 35 and clearly demonstrated that BCG reduced tumour 
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recurrence in a low-risk population. In a high-risk group in which all patients 
treated with TUR alone had tumour recurrence by 9 months, Pinsky 
similarly observed a marked reduction in the rate of tumour recurrence with 
BCG treatment .36 
 
Subsequent follow-up of patients enrolled in these two initial 
controlled trials have confirmed that the benefit of BCG treatment, unlike 
that of intravesical chemotherapy, is long term. Protection from tumour 
recurrence in both studies lasted more than 5 years. The fact that disease 
progression, as well as recurrence, appeared to be reduced with BCG was 
impressive, and in 1985,  
D Lamm  reported a significant reduction in stage progression in patients involved 
in his initial trial .37 Herr reported an even more impressive benefit of BCG treatment in 
1988. In 86 randomized patients, progression to muscle invasion or metastasis was 
significantly delayed with BCG treatment (p<0.02) and mortality reduced from 32% in 
controls to 14% with BCG treatment38 . Subsequent controlled studies by Pagano have 
confirmed this finding.39 
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Mechanism of Action 
             BCG is currently the most effective intravesical agent for the 
treatment and prophylaxis of superficial bladder cancer. BCG is recognized 
as a nonspecific immune stimulant. Intravesical BCG induces inflammation 
of the bladder with infiltration of a broad range of cell types. BCG may 
activate macrophages, T lymphocytes, B lymphocytes, natural killer cells 
(NK), and killer cells.40 Intravesical BCG immunotherapy results in cytokine 
production, including interleukins 1(IL-1), 2(IL-2), and 6(IL-6), interferon 
gamma, and tumor necrosis factor alpha (TNF-a)41 which can be measured 
in the urine for many hours after instillation. McAveray et al.42 reported that 
BCG induces a local Type II immunologic response which may be mediated 
by Interleukin (IL) 4; IL-4, IL-10, the later cytokines may suppress cell-
mediated responses. These cytokines also cause a shift to Type I response 
with the subsequent development of a protective antitumor response.  
Ratliff et al.43 investigated the role of CD4 and CD8 lymphokines in 
the antitumor response of BCG and reported that there is no evidence of 
induction of protective systemic immunity after BCG. However, they 
reported a requirement of T-lymphocytes, and CD4 and CD8 subsets in 
BCG-mediated antitumor activity. They concluded that BCG-mediated 
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antitumor activity is a localized phenomenon. BCG stimulates cytokine 
production, and this in turn enhances NK cell activity, which increases after 
BCG immunotherapy.44,45 Conti et al.46 reported that immunotherapeutic 
effects of BCG in bladder cancer patients are related to its capacity to prime 
macrophages that enhance the release of TNF-a and IL-I alpha, which are 
involved in tumor killing. BCG produces a T-cell mediated immune 
response that has been linked to antitumor activity in both humans and 
mice.47 The antineoplastic effect of BCG is most likely the result of a 
combination of enhanced activity of various arms of the immune system. 
 
            After intravesical instillation, live mycobacteria attach to the 
urothelial lining, facilitated by fibronectin, a component of the extracellular 
matrix.48 Integrin is required for the direct attachment and internalization of 
BCG by bladder tumor cells.48-50 This process leaves bacterial cell surface 
glycoproteins attached to epithelial cell membranes, and this antigen is 
thought to mediate the immune response.51 Tumor cell motility is also 
thought to be inhibited by BCG through a mechanism involving the BCG-
fibronectin-tumor cell interaction.52 Bladder biopsies following BCG 
administration show increased expression of human leukocyte antigen 
(HLA)-Dr antigen on tumor cells and infiltration of tumor and stroma with 
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lymphocytes, predominantly T helper cells, and macrophages. The 
helper/suppressor ratio in infiltrating lymphocytes is increased. Changes in 
peripheral blood are also seen, including heightened immunoproliferative 
response to BCG antigen and production of specific antibody.53,54 
Principles of BCG Immunotherapy 
 
               To use immunotherapy effectively in the management of bladder 
cancer or other malignancy, it is important to consider basic principles and 
understand the differences between immunotherapy and chemotherapy. 
Currently chemotherapy is limited in specificity, and basically inhibits or 
destroys rapidly dividing cells. Generally, tumor cell destruction is 
proportional to drug concentration so treatments are pushed to the limit of 
tolerance. In contrast, immunotherapy may be either nonspecific or specific. 
More often than not, optimal responses to immunotherapy are seen at less 
than the maximum tolerated dose because high doses invoke complex 
immune regulatory mechanisms. The typical dose response curve with 
biological response modifiers such as BCG is therefore bell shaped with 
optimal response occurring at intermediate doses. 55 
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            The optimal dose of BCG remains to be defined, and may, like the 
optimal treatment schedule, vary from patient to patient. Current data 
suggest that intravesical doses between one hundred million (1 x 108) and 
one billion (1 x 1010) colony-forming units (CFU) are effective, but 
responses have been reported with doses as low as 10 million CFU or 1 mg 
BCG.56 The wide variation in effective clinical doses probably relates to the 
mode of administration. In intravesical instillation, only those organisms that 
attach to the bladder wall stimulate an immune response. Therefore, 
consideration must also be given to avoid administration of medications that 
can limit the effectiveness of the dose given. Agents that inhibit clot 
formation reduce fibronectin expression, which may reduce BCG 
attachment, immune stimulation, and antitumor activity.57 - 59 Similarly, 
concern has been raised that administration of antitubercular antibiotics such 
as isoniazid (INH), which inhibit intravesical BCG attachment and immune 
stimulation in the guinea pig model60, may also reduce the efficacy of BCG 
therapy. However, Stassar et al.61 reported that INH does not impair the local 
immunological stimulation after intravesical BCG. Until additional data 
becomes available, INH, trimethoprim/sulfamethoxazole, and quinolones 
should be used with caution in patients receiving BCG. However, these 
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antibiotics should be used without hesitation to treat the side effects of BCG 
or intercurrent infection. 
Efficacy of BCG Immunotherapy  
 
          Long-term follow-up studies have consistently demonstrated 
prolonged protection from tumor recurrence by BCG62-64 as well as 
increasing evidence to suggest that optimal BCG intravesical 
immunotherapy also reduces tumor progression and mortality.62-65 All six 
clinical studies comparing surgery alone with intravesical BCG 
immunotherapy demonstrated a highly significant advantage of BCG 
treatment 65-70. Direct randomized comparisons of BCG immunotherapy with 
intravesical chemotherapy have also demonstrated a statistically significant 
decrease in tumor recurrence rate with BCG compared with thiotepa, 
doxorubicin, and mitomycin C (MMC)71-78.  
The Southwest Oncology Group recently compared TICE BCG 
(50mg) and MMC (20mg) in 469 randomized high-risk patients with stage 
Ta or T1 disease.77 Both treatments were given weekly for six weeks then 
monthly for one year. A 20mg dose of MMC was previously reported to be 
the optimum dose 78. In the MMC arm, tumor reoccurred in 33% of patients 
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with a median time to recurrence of 18.4 months. With a median follow-up 
of 30 months, 60% of patients in the BCG arm were without tumor 
recurrence as opposed to 46% of patients in the MMC arm (p=0.017). No 
toxicity was seen in 18% of the BCG arm or in 30% of the MMC group 
p<0.003). Melekos et al.79 reported a recent series of 161 patients enrolled in 
a three-arm study of intravesical prophylaxis with epirubicin versus BCG 
versus transurethral resection (TUR) alone. Lamm et al reported that 60% of 
epirubicin-treated patients, 68% of BCG-treated patients, and 41% of control 
subjects remained free from recurrences at a median follow-up of 33 
months. Epirubicin and BCG were both superior to TUR alone; however, 
BCG was significantly better than epirubicin in preventing recurrence of 
stage T1 and high-grade tumors. Cookson and Sarosdy80 also demonstrated 
the effectiveness of BCG in high-risk stage T1 patients in their trial; 91% of 
those treated with intravesical BCG immunotherapy were free of disease at a 
meanfollow-up of 59 months. 
 
         The effect of BCG on tumor progression has been investigated in three 
randomized studies, each of which found a statistically significant reduction 
in progression to muscle invasion or metastasis. Lamm demonstrated a 
reduction in progression to muscle invasive disease in 8% of controls 
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compared to 3% in the BCG group.65 This positive impact on progression 
has resulted in improved survival. A controlled trial from Memorial Sloan-
Kettering showed persistent reduction in both tumor recurrence and 
progression after ten years follow-up. However, the reduction in tumor 
progression did not extend to fifteen years. Overall, 53% of high-risk 
patients had progression with a disease-specific survival of 63%. Thus, even 
after apparent successful treatment with BCG, patients remain at risk for 
progression, recurrence, and mortality and require vigilant long-term 
surveillance. In another report, Herr et al.81 reported that within a median 
follow-up of eight months, mortality rate was reduced from 32% in TUR 
alone patients to 14% in BCG-treated patients (p<0.032). Herr and 
associates reported that BCG improved a five-year survival to 87% versus 
63% for TUR (p=0.016).64 This author has also reported that cancer deaths 
were reduced from 37% to 12% (p<0.01) and that the cystectomy rate was 
reduced from 42% to 26% (p<0.0001) in patients with BCG.81 Nadler et al.63 
demonstrated the durability of a single course of BCG which kept 28% 
(29/104) of the patients tumor-free at 11 years. However, of the 66 patients 
who received a second six-week course of BCG for recurrent tumors after 
failing the intravesical six-week course, 27(41%) remained tumor-free at 11 
years. Witjes et al.82 confirmed that effectiveness of BCG in reducing tumor 
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progression in high-risk patients who had failed prior intravesical 
chemotherapy for recurrent superficial TCC. 
 
             BCG is also effective in the intravesical treatment of CIS. With over 
1,000 patients from several series, the average complete response rate of CIS 
to BCG is in excess of 70%.83 By comparison, complete response rates for 
chemotherapy average less than 50%, and in general, fewer than 20% of 
patients treated with chemotherapy  remain disease-free long-term.62 
 
              In contrast to intravesical chemotherapy, data suggest that 
maintenance therapy with BCG improves long-term results. In a recent 
report by the Southwest Oncology Group77 with optimal BCG 
immunotherapy for recurrent superficial transitional cell carcinoma (CIS, 
Ta, T1), the complete response (CR) rate was 87% and long-term disease-
free status was maintained in 83% of patients. In CIS patients treated with 
BCG, the complete response at six months post-therapy is increased from 
73% to 87% (p<.04) with three additional instillations given at six monthly 
intervals for maintenance.62 Maintenance BCG using three weekly 
instillations increased long-term disease-free status from the expected 65% 
to 83%. In patients with papillary TCC, maintenance BCG given in a series 
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of three weekly treatments at three months, six months, and every six 
months for three years, dramatically reduced tumor recurrence (p<.0001) 
when compared with a single six-week course .85 Long-term disease-free 
status was increased from 50% in the induction-only group to 83% in the 
maintenance therapy group (p<0.000001). More importantly, this 
maintenance therapy has resulted in statistically significant improvement of 
patient survival as compared to induction-only.  
In 391 randomized patients, the excellent 86% survival at four years 
observed with induction therapy was improved to 92% in patients receiving 
maintenance BCG (p<0.04)85. The current recommended maintenance BCG 
regimen ñ and the only regimen found to be superior to a single, six-week 
induction ñ employs three weekly instillations of 105 to 108 CFU of 
Connaught BCG, three months after initiation of treatment.85 Three weekly 
instillations are repeated at six monthly intervals for three years. The second 
or third weekly maintenance treatment is given only if the preceding 
instillation was without increased side effects. Investigators have reported 
that in low-dose BCG, 27mg/3x108 CFUs were efficacious, yielding a CR of 
84%,68 and some have seen a reduction in toxicity. 
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  It has been suggested that the efficacy of BCG can be improved 
further by high-dose vitamins89. Lamm et al.86 reported that daily high-dose 
vitamins A, B6, C, and E versus recommended daily allowances (RDA) 
produced further protection from recurrence in patients treated with BCG. 
The five-year estimates of tumor recurrence were 91% in the RDA group 
and 41% in the mega dose vitamin group. Overall recurrence was 24 of 30 
(80%) patients in the RDA group, and 14 of 35 (40%) in the high-dose 
arm86. Further research is needed to confirm this study and identify which 
specific vitamins offer the protection from tumor recurrence. Other attempts 
to improve BCG immunotherapy, such as the addition of intradermal BCG 
inoculation, have not yet been successful.86 
Complications of BCG Intravesical Therapy 
 
              Intravesical BCG presumably stimulates an immune response to the 
tumor and thus is associated with unique side effects. Dysuria and urinary 
frequency are expected as a consequence of the inflammatory response, and 
cystitis is the most frequent adverse reaction-occurring in up to 90% of 
cases.87,88 Hematuria may occur with cystitis and is seen in one-third of 
patients.88 Irritative bladder symptoms are unlikely in the week after the first 
intravesical BCG.88 Side effects of BCG generally increase with successive 
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treatments, unless the dose of antibiotics is reduced or prophylactic 
antibiotics are given. Patients with symptoms lasting more than 48 hours can 
be treated with 300mg INH daily.91 This treatment is continued only while 
the symptoms of hematuria and cystitis persist and is reinstituted one day 
before subsequent BCG instillation and continued for three days. According 
to Stassar and associates61, INH does not impair the local immunological 
stimulation after intravesical BCG or the efficacy of BCG. BCG treatments 
are postponed until all side effects from previous instillations have resolved. 
BCG is a live organism, and even though virulence has been dramatically 
attenuated, regional or systemic infection may occur. 
 BCG organisms usually are gone within a few days of instillation but 
have been reported to persist in the urinary tract for at least 16.5  months 
after intravesical BCG.90 Initial estimates of the incidence of BCG sepsis 
were in the range of 0.04% and 10 patients died following intravesical 
BCG.87 The incidence of sepsis has dropped dramatically after the 
precaution of not administering BCG after traumatic catheterization or in the 
presence of continued symptoms of BCG infection. When BCG sepsis does 
occur, we now recommend INH 300mg, rifampin 600mg, and prednisone 
40mg daily. Prednisone is continued until sepsis abates and is then tapered 
gradually over the next two to four weeks. Rifampin and INH are continued 
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for three to six months, depending on the severity and duration of the 
reaction. Animal studies have confirmed that this regimen significantly 
improves survival89 and no patient receiving this regimen has died of BCG 
sepsis. The diagnosis of BCG sepsis is made by clinical presentation with 
high fever, shaking chills, and then hypotension. It is important to proceed 
with antibiotic treatment without waiting for culture results when systemic 
BCG infection is suspected. Typically, cultures are negative, even in the face 
of clinical sepsis. Molecular techniques to identify BCG DNA may prove 
useful in the future.91 
 
BCG versus lntravesical Chemotherapy 
 
In a randomized prospective comparison, Brosman was 
the first to demonstrate that BCG treatment was superior 
to intravesical chemotherapy with thiotepa 92. In his study, a 6-week course 
of weekly instillations followed by monthly BCG treatment resulted in a 
remarkable 0% recurrence with BCG treatment compared with 47% 
recurrence with thiotepa. 
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 In a Brazilian study comparing high doses of oral BCG (Moreau RI) 
with thiotepa, Netto and Lemos also found high-dose oral BCG to be 
superior to thiotepa chemotherapy 93. 
 
BCG has similarly been compared with intravesical doxorubicin in a 
Southwest Oncology Group (SWOG) study. In the first report of this study, 
BCG was found to be superior to doxorubicin in both the treatment of CIS 
and the prophylaxis of recurrent TCC 94. In CIS, complete response was 
initially seen in 47% of 57 doxorubicin-treated patients and 71% of 52 BCG 
treated patients. In papillary TCC, tumour recurrence was reduced from 79% 
in 67 doxorubicin-treated patients to 57% in 60 BCG treated patients. 
Subsequent long-term follow-up of these patients has provided further 
evidence of the long-term benefit of BCG treatment 95.  
 
With an average follow-up of 65 months, it is now estimated that only 
18% of patients with CIS treated with doxorubicin will be disease-free for 5 
years, compared with 45% of those treated with BCG. Of patients with CIS 
who had complete response to BCG, 64% remained disease-free for 5 or 
more years. In patients  with TA or T1 tumours, 17 and 37%, respectively, 
are estimated to remain disease-free for 5 years.  
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Maintenance BCG 
As previously stated, the 6-week treatment schedule originally 
conceived by Morales is remarkably close to the optimal schedule. In 
uncontrolled trials, however, Kavoussi and associates reported evidence that 
a single 6- week course of intravesical BCG was suboptimal96 . 
‘Response’, which included eradication of CIS or residual 
papillary tumour as well as prevention of tumour recurrence, was seen in 
38% of patients treated with a single 6- week course and 60% of patients 
treated with a second 6- week course. The obvious assumption that a 
continuous 12-week course (as described by Brosman) is superior to 6 
treatments, surprisingly, proved to be incorrect. The dose-response  curve of 
BCG, like that of many biological response modifiers, is bell shaped 97. 
Excess BCG can, infact, reduce the antitumour response. In subsequent 
studies, the recurrence rate with a continuous 12-week course of BCG was 
high, and evaluation of the immune response by in vitro 
immunoproliferative assays demonstrated an actual reduction in immune 
stimulation in these patients . 
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Three studies have reported comparisons of maintenance and 
nonmaintenance therapy. In D Lamm’s initial report, patients who were 
originally randomized to no treatment were offered maintenance BCG 98. A 
4-fold reduction was observed in the rate of tumour recurrence, but not 
incidence, in the maintenance group. In a properly randomized high-risk 
population of 93 patients, Badalament gave 6-week treatments with or 
without monthly maintenance instillations 99. In that study, there was no 
reduction in the incidence or time to onset of tumour recurrence. The rate of 
tumour recurrence did appear to be reduced with maintenance, from 0.148 
tumours/month in the nonmaintenance group to 0.071 tumours/month with 
maintenance BCG, but this difference was not statistically significant.  
 
In a similar smaller study, Hudson evaluated instillations every 3 
months as a maintenance schedule and again saw no significant reduction in 
the incidence of tumour recurrence 100. Animal studies have confirmed that 
retreatment, as expected, improves the antitumour response when given at a 
time when the initial immune stimulation has waned .101 
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 The controversy should soon be answered, as 550 patients enrolled 
since 1985 have entered a SWOG comparison of  maintenance and non-
maintenance  BCG therapy. 
 
 
Carcinoma in situ 
 
 Multiple trials have demonstrated the efficacy of BCG in the 
treatment of CIS. Complete response rates average over 70%, and the 
duration of response in most studies has been excellent. With an average 
response rate of 70% or more, it is difficult to    demonstrate statistically 
significant improvement. Surprisingly, the SWOG study comparing 
maintenance and nonmaintenance BCG, with only 150 randomized CIS 
patients, was able to demonstrate significant improvement in complete 
response 102. In patients given 6 weekly intravesical plus percutaneous 
Connaught BCG treatments, complete response at 3 months was 61% in the 
nonmaintenance group and 56% in the maintenance group (not significantly 
different). With no additional BCG in the nonmaintenance group an 
additional 9% of patients went on to achieve a complete response by 6 
months after initiation of treatment, yielding the  expected 70% complete 
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response rate. With just 3 additional weekly BCG treatments at 3 months, 
complete response increased by 26% by 6 months (p<0.02), yielding an 
overall complete response rate of 82% (p<0.04), This ‘6 plus 3’ regimen (i.e. 
a normal 6-week induction schedule followed by a 6-week rest, then a 
further 3 weekly treatments) must, now be considered the optimal induction 
schedule for patients undergoing BCG treatment for carcinoma of the 
bladder.  
 
Extensive evaluations of BCG immunotherapy confirm that BCG is 
the treatment of choice at this time for patients with CIS and potentially 
aggressive stage TA and T1 TCC of the bladder. Long-term randomized 
controlled trials confirm that, unlike chemotherapy, the benefits of BCG 
treatment are long term, and can be translated into a pro-longed decrease in 
the incidence and rate of tumour recurrence, tumour progression, need for 
cystectomy, and mortality from bladder cancer. Controlled comparisons with 
intravesical chemotherapy confirm the superiority of BCG over thiotepa and 
doxorubicin. While the optimal treatment schedule is still under 
investigation, a statistically significant increase in complete. response is 
demonstrated when an additional 3 weekly treatments are given at 3 months 
after initiation of the standard 6 weekly treatments. 
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Maintenance BCG will not be needed until the beneficial immune 
response from induction has waned. The value of maintenance BCG 
treatments at 6-month intervals is under investigation. In experienced hands, 
BCG immunotherapy  is very safe and highly beneficial to patients who are 
at risk of multiple recurrences or progression of bladder cancer.  
 
Interferon Alfa in The Treatment Of Superficial Bladder Cancer 
 
Interferon-Alfa (IFN-a) is a biological response modifier that  has 
both direct and indirect action against  transitional  cell carcinoma (TCC), 
the most common type of bladder  cancer.  While intravesical IFN-a  
monotherapy  for superficial bladder  cancer has limited total  effectiveness  
vis-a-vis chemotherapy or BCG, it can induce long term remissions even in 
patients that  have  failed  other forms of therapy and does so with a very 
favorable toxicity profile causing little to no cystitis. 
Recently, combining intravesical IFN-a  with  chemotherapy or BCG 
is emerging as a new treatment  strategy. Preliminary studies of  IFN -a  plus  
Mitomycin  suggest  additive  efficacy. 
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Combination  therapy of IFN-a  with  BCG  appears especially 
promising. As a mixed intravesical preparation,  these  two agents are 
completely biocompatible.   
Experimental  testing of BCG/IFN-a combination therapy 
demonstrates a favorable profile on all aspects  of  the BCG/tumor/immune 
system  interaction.  Direct toxic effects of BCG on  human  bladder cancer 
lines is enhanced by the addition of IFN-a.  The combination also 
synergistically  enhances direct cytokine  production by tumor cells, reduces 
proliferation and upregulates tumor  surface markers  including  
histocompatibility antigens and the  apoptotic orchestrator Fas.  This makes 
the tumor a better target for immune cell recognition  and  destruction.  
Furthermore, IFN-a  strongly polarizes the human  cellular  immune 
response to BCG in the direction of the favorable T-helper type one (TH1)  
pathway  by down-regulating  the antagonistic cytokine IL-10 while 
upregulating the expression of TNF-a,  IL-12, and IFN-gamma. Substantial 
amplifications in IFN-   production are achieved against human  
lymphocytes during in vitro testing, averaging approximately 40-fold while  
allowing up to  a 100-fold reduction in BCG dose. This feature of IFN-a 
essentially enhances the body’s natural immune response to BCG. 
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Safety and efficacy studies of combination BCG  plus IFN therapy in 
animal models are similarly encouraging. IFN-ß, closely related to IFN-a,  
protects  against  infection by a related mycobacterial pathogen MAI. BCG  
plus IFN-a  or  BCG  plus  the interferon inducer  bropiramine are more 
effective than either agent alone in the murine MBT-2 and MB-49 bladder 
cancer models. 
 
Sever et al  pilot  clinical  studies  using  combination  intravesical  
immunotherapy  against superficial bladder  cancer have shown promising 
results. Bercovich (1995)  found half  dose BCG  plus low-dose (10 MU) 
IFN-a-2B to provide equivalent tumor  prophylaxis to full dose BCG  but 
with reduced toxicity.  Stricker  (1996) reported complete and  partial 
response rates at 12 months for 9/12 and 2/12 patients, respectively, all with 
aggressive histology. Half dose BCG was given together with IFN- a-2B 
titrated from 10-100 MU with no serious adverse events.  Esuvaranathan 
(2000) has  reported a reduction of recurrence rate from 50% to 30% to 10% 
at 19 months in a randomized study of 8 0 patients treated with full-dose 
BCG  vs. 1/3 dose BCG  vs. 1/3  dose BCG  plus 10  MU IFN -a, 
respectively.  Patient  tolerance  was  also  improved in the combination arm. 
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 The early results of an open-label combination study by O'Donnell 
(2000) in 38 high risk patients  with superficial TCC that had all previous 
failed BCG is  similarly encouraging. Using 50-100 MU of IFN-a-2B plus 
BCG in doses  ranging  from  full to  1/100th  standard dose, titrated  down 
by prior exposure and tolerance especially during the maintenance phase, 
complete  response rates at 26 months  median follow-up is 56% even for 
patients that  have  failed  BCG  monotherapy  two or more times before. 
Toxicity has been no different than  with  BCG  alone. Urinary IFN-   levels 
are enhanced or maintained at high levels during therapy. 
The  use of  IFN -a  as  part of a multidrug  cytotoxic 
chemotherapeutic regimen for advanced urothelial cancers remains  
provocative. The initial  reports of Logothetis et al. showing 30% and 60% 
PR with IFN-a  combined with 5-FU or  5-FU plus platinum, respectively, 
have not yet been repeated.  Parnis  (1997)  found IFN -a  plus  cisplatinum 
to be historically equivalent to cisplatinum alone (35% PR) in a phase II trial 
involving 22 patients. 
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RESULTS AND DISSCUSSION 
 
Patient demographics 
The results and analysis of the data on 31 patients who underwent 
intravesical therapy with only 120 mgs of  BCG  ( GROUP A )  and 30 
patients who underwent intravesical therapy with 60mgs of BCG and 6 MIU 
of Interferon alfa 2b (GROUP B ) are described in this section. 
An over view of the demographics of the study population is shown 
first followed by the results of the study. 
Sex distribution  
Table 1:  Sex distribution 
GROUP 
A B 
Total 
SEX 
Count % Count % Count % 
Female 15 48.39 8 26.67 23 37.70
Male 16 51.61 22 73.33 38 62.30
Total 31 100.00 30 100.00 61 100.00
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Age distribution 
Table 2: Age Distribution 
GROUP 
A B 
Total 
Age 
Count % Count % Count % 
35 - 45 3 9.68 3 10.00 6 9.84 
45 - 55 6 19.35 7 23.33 13 21.31
55 - 65 9 29.03 10 33.33 19 31.15
65 - 75 9 29.03 4 13.33 13 21.31
75 - 85 4 12.90 6 20.00 10 16.39
Total 31 100.00 30 100.00 61 100.00
 
 
Study population was a total of 61 patients out of which 38 males and 
23 females were present. Group A had equal male and female distribution 
while group B had a skew towards males with 73 males and 27 females. 
 
The mean age group was 62 years and majority of the patients in both 
groups (A and B) were in the 55 – 65 yrs of age. The next major group was 
65 to 75 yrs with 13 patients. 
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Tumor stage distribution 
Table 3: Tumor stage distribution 
GROUP 
A B 
Total 
STAGE 
Count % Count % Count % 
CIS 8 25.81 8 26.67 16 26.23
T1 19 61.29 19 63.33 38 62.30
TA 4 12.90 3 10.00 7 11.48
Total 31 100.00 30 100.00 61 100.00
 
 
62% of the patients were in T1 while 26% were in CIS and the rest were in 
the Ta group. 
All patients who had Ta with grades 1 and 2 were excluded from the study. 
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Grade distribution  
Table 4: Grade Distribution 
GROUP 
A B 
Total 
GRADE 
Count % Count % Count % 
CIS 8 25.81 8 26.67 16 26.23
G1 4 12.90 4 13.33 8 13.11
G2 13 41.94 11 36.67 24 39.34
G3 6 19.35 7 23.33 13 21.31
Total 31 100.00 30 100.00 61 100.00
 
As can be seen from this table the study population had a healthy mix of all 
grades with 39% grade 2 tumors and 21% being grade 3 and 13 % was grade 
1.  The remaining 26 % was CIS tumors. So this table shows that there was 
no particular grade that was able to skew results and the maximum was CIS 
and Grade 3 tumors combined. 
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Adverse factors  
Size more than 3 cms 
Table 5: Size 
GROUP 
A B 
Total 
SIZE 
Count % Count % Count % 
< 3 cms 15 48.39 10 33.33 25 40.98
> 3 cms 16 51.61 20 66.67 36 59.02
Total 31 100.00 30 100.00 61 100.00
 
 
Excluding CIS patients all other patients with Ta and Ti group were taken up 
for this evaluation and out of these tumors nearly 60 % were more than 3 
cms in size at the time of resection.  
  67 % of group B had size more than 3 cms compared to only 51% of  
Group A. 
Hence more number of patients in BCG + IFN group had this adverse 
prognostic factor. 
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Multifocality 
 
Table 6: Multifocality 
GROUP 
A B 
Total 
MULTIFOCALITY 
Count % Count % Count % 
< 3 area 24 77.42 20 66.67 44 72.13
> 3 area 7 22.58 10 33.33 17 27.87
Total 31 100.00 30 100.00 61 100.00
 
72 % of the patients had lesions than were not multifocal and only 27 % had 
multifocality. 
But out of this, group B had 33% of its total with multifocality while  
group A had only 22%. 
Hence more number of patients in BCG + IFN group had this adverse 
prognostic factor. 
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Incomplete resection 
 
Table 7: Completeness of resection 
GROUP 
A B 
Total 
RESECTION 
Count % Count % Count % 
Complete 31 100 28 93.33 59 96.72
Incomplete   2 6.67 2 3.28 
Total 31 100 30 100.00 61 100.00
 
Only 2 patients had incomplete resection with a small portion being left 
behind in than anterior wall close to the bladder neck. Both these patients 
belonged to the BCG + IFN group. One of the exclusion criteria was to 
exclude extensive superficial tumors that precluded complete resection. But 
these two patients more than 90% of the growth were resected and hence 
were considered candidates for the study. 
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Appearance  
Table 8: Appearance  
GROUP 
A B 
Total 
APPEARENCE 
Count % Count % Count % 
CIS 8 25.81 8 26.67 16 26.23
PAPILLARY 21 67.74 19 63.33 40 65.57
SESSILE 2 6.45 3 10.00 5 8.20 
Total 31 100.00 30 100.00 61 100.00
 
Majority of the patients had papillary growth – 65% while the next major 
group was CIS 
With about 26% and about 8% had sessile growths. None of our patients had 
both a combination of CIS and papillary growths.  
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Response to treatment 
Table 9: Response 
GROUP 
A B 
Total 
RESPONSE 
Count % Count % Count % 
CR 23 74.19 25 83.33 48 78.69
NR 2 6.45 2 6.67 4 6.56 
PR 6 19.35 3 10.00 9 14.75
Total 31 100.00 30 100.00 61 100.00
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Complete response for both the groups combined with a minimum 
follow up of 21months and a maximum follow up of 28months with a 
combined total combined follow up of up to 1431 months.  The complete 
response was 78 % with partial response about 14 % and no response about 
6% at the end of the study period. 
 
 Most of the recurrences were within 6 months of the first instillation. 
No response patients were diverted to radical cystectomy. 
 Partial response patients underwent second TURBT and were put on 
the same protocol of intravesical chemotherapy. 
 
 
 When group A (BCG) is taken, complete response is about 74% and 
partial response is 19%. 
 Group B (BCG + IFN) complete response is 83% and partial response 
of 10%.Both groups had a failure rate of 10 %( no response – cystectomy) 
This important table shows us that group B had a higher complete 
response rate when compared to the group A. This difference assumes 
significance when we consider that group B had more adverse factors as 
shown in the previous pages. 
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Table 10: Recurrence 
GROUP 
A B 
Total 
RECURRENCE 
Count % Count % Count % 
No 23 74.19 25 83.33 48 78.69
Yes 8 25.81 5 16.67 13 21.31
Total 31 100.00 30 100.00 61 100.00
 
Here we see that 26 % of BCG group had recurrences while only 16% of 
BCG + IFN had recurrences.  
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Stage and grade wise response 
Table 11: Stage and response 
STAGE 
CIS T1 TA 
Total 
RESPONSE 
Count % Count % Count % Count % 
CR 13 81.25 31 81.58 4 57.14 48 78.69 
NR 2 12.50 2 5.26   4 6.56 
PR 1 6.25 5 13.16 3 42.86 9 14.75 
Total 16 100.00 38 100.00 7 100.00 61 100.00
 
Grade 3 tumors have fared badly in both the groups. But we also see 
that stage wise Ta tumors have not fared well even though they are only Ta 
when compared to T1. This can be explained by the fact that only TaG3 
tumors are included in the study while T1G1 and G2 tumors can skew the 
results in favor of T1. 
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Table 12: Grade and response  
GRADE 
 G1 G2 G3 
Total 
RESPONSE 
Count % Count % Count % Count % Count % 
CR 13 81.25 7 87.50 22 91.67 6 46.15 48 78.69
NR 2 12.50     2 15.38 4 6.56 
PR 1 6.25 1 12.50 2 8.33 5 38.46 9 14.75
Total 16 100.00 8 100.00 24 100.00 13 100.00 61 100.00
P < 0.05 
 
 
 
 
Stage for stage Grade is more important and grade for grade stage is most 
important. The order of priority should be stage and then grade of tumors. 
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Size and response: 
Table 13: Size and response 
SIZE 
< 3 cms > 3 cms 
Total 
RESPONSE 
Count % Count % Count % 
CR 23 92 25 69.44 48 78.69
NR 1 4 3 8.33 4 6.56 
PR 1 4 8 22.22 9 14.75
Total 25 100 36 100.00 61 100.00
Table 14: Multifocality and response 
MULTIFOCALITY 
< 3 area > 3 area 
Total 
RESPONSE 
Count % Count % Count % 
CR 34 77.27 14 82.35 48 78.69
NR 3 6.82 1 5.88 4 6.56 
PR 7 15.91 2 11.76 9 14.75
Total 44 100.00 17 100.00 61 100.00
Tumors more than 3 cms in size have fared badly with only 70 % complete 
response and tumors with less than 3 cms have had 90% complete response. 
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Incomplete resection and response 
Table 15: Incomplete resection and response 
RESECTION 
Complete Incomplete
Total 
RESPONSE 
Count % Count % Count % 
CR 48 81.36   48 78.69
NR 4 6.78   4 6.56 
PR 7 11.86 2 100 9 14.75
Total 59 100.00 2 100 61 100.00
P < 0.05 
 
 
Incompletely resected tumors fared badly. Only 2 patients had incomplete 
resection and both the patients had a recurrence. 
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Survival function 
Survival Functions
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Kaplan – Meier curve for the above 2 groups show a slightly better result for 
BCG + IFN vs. BCG alone group. Though this may not be statistically 
significant a longer follow up may yield better results. Even so the primary 
hypothesis that half dose BCG + IFN combination is equally if not better 
effective than BCG alone. 
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Toxicity profile 
Table 16: Hematuria 
GROUP 
A B 
Total 
HEMATURIA 
Count % Count % Count % 
No 22 70.97 28 93.33 50 81.97
Yes 9 29.03 2 6.67 11 18.03
Total 31 100.00 30 100.00 61 100.00
P < 0.05 
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Table 17: Fever and chills  
GROUP 
A B 
Total 
FEVER 
AND 
CHILLS Count % Count % Count % 
No 21 67.74 24 80.00 45 73.77
Yes 10 32.26 6 20.00 16 26.23
Total 31 100.00 30 100.00 61 100.00
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Table 18: Myalgia etc  
GROUP 
A B 
Total 
MYALGIA, 
MALAISE, 
ARTHRALGIA, Count % Count % Count % 
No 23 74.19 29 96.67 52 85.25
Yes 8 25.81 1 3.33 9 14.75
Total 31 100.00 30 100.00 61 100.00
P < 0.05 
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Table 19: Cystitis, dysuria  
CYSTITIS,DYSURIA, 
FREQUENCY,URGENCY 
NO OF PATIENTS DISCOMFORT 
SCORE 
GROUP A 31 4.16 
GROUP B 30 2.6 
Marked by patients on a visual analogue scale of 1 to 5 with one being the 
least troublesome and 5 the worst. 
 
 
 
We have already shown that  BCG + IFN combination is as efficacious as  
BCG alone, but when we consider the side  effect profile and toxicity of both 
the groups we can see that BCG + IFN is significantly better in all respects. 
None of the patients had any serious side effects like BCGosis etc that 
necessitated stoppage of treatment. No patient needed to be started on Anti 
tuberculosis treatment 
 
Less hematuria, less cystitis like features, less myalgia, arthralgia and 
malaise with more than 80% not having fever group B has a much lower 
side effect profile. 
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This in turn has two significant benefits 
1. It reduces the number of physician visits that the patient has to 
undergo because of the treatment related side effects. 
2. Symptomatic therapy for the side effects is also reduced thereby  
saving both man-hours as well as the cost of drugs 
 
But this has to be weighed against the increased cost of the BCG + IFN 
combination. 
BCG 60 mgs + IFN (6 miu) = Rs 1600 
BCG 120 mgs = Rs 750. 
If cost was not included in the equation then the patient should always prefer 
an equally effective but less toxic. Therapy = BCG + IFN 
The limitations of the study are the small study population and limited 
follow up.To reach definitive conclusions we need to have a multicentric 
trial with a larger study population and a much longer follow up because 
bladder cancer natural history is such that definitive conclusions need more 
follow up 
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CONCLUSION 
 
BCG (60 mgs) + IFN alpha 2b (6 Miu) combinations is equally if not better 
effective than BCG (120 mgs) alone as intravesical therapy for superficial 
bladder cancer. 
 
Side effects of the combination therapy are significantly better for the 
combination treatment though its cost is also higher when compared to BCG 
alone. 
 
Definitive role for IFN + BCG combination as a first line therapy exists. 
 
Larger multicentric trials with a bigger study population and longer follow 
up are required to come to definitive conclusions. 
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